Read More

Generating a broad portfolio of novel agents with best-in-class potential.

Development Pipeline

Driving meaningful advances to address chronic inflammation.

We’re committed to evolving immunology, with a pipeline that includes programs specifically targeted to address inflammatory diseases demonstrating clear, unmet needs. The disease pathways under investigation by Evommune exert influence on a multitude of disease areas, and the modulation of mast cell and T-cell activity shows promise in multiple established patient populations.

Program
Target
Indication
  • Discovery
  • Pre-Clinical
  • Phase 1
  • Phase 2
  • Phase 3
MRGPRX2
Chronic Inducible Urticaria Chronic Spontaneous Urticaria Atopic Dermatitis/Inflammatory Itch Other Indications
IL-18
Atopic Dermatitis Other Indications
PKCϴ
Inflammatory Bowel Disease

Program
Target
MRGPRX2
Indication
Stage
Chronic Inducible Urticaria
Chronic Spontaneous Urticaria
Atopic Dermatitis/Inflammatory Itch
Other Indications
Phase 2
Phase 1
Phase 1
Phase 1
Program
Target
IL-18
Indication
Stage
Atopic Dermatitis
Other Indications
Phase 1
Pre-Clinical
Pre-Clin.
Program
Target
Indication
Stage
Inflammatory Bowel Disease
Discovery
Discov.

Learn about our ongoing clinical trials for our investigational therapies.